Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “High Risk Essential Thrombocythemia”

36 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 36 results

Not applicableStudy completedNCT02953704
What this trial is testing

Myelofibrosis and Essential Thrombocythemia Observational Study (MOST)

Who this might be right for
MPN (Myeloproliferative Neoplasms)
Incyte Corporation 1,469
Post-approval studies (Phase 4)Study completedNCT03232177
What this trial is testing

Anagre Cap. in Patients With High-Risk Essential Thrombocythemia

Who this might be right for
Essential Thrombocythemia
Yuhan Corporation 70
Post-approval studies (Phase 4)Study completedNCT00202644
What this trial is testing

Anagrelide and Hydroxyurea in High-Risk Essential Thrombocythemia Patients

Who this might be right for
Thrombocythemia, Hemorrhagic
Shire 150
Large-scale testing (Phase 3)Looking for participantsNCT05198960
What this trial is testing

AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms

Who this might be right for
Polycythemia VeraEssential ThrombocythemiaPrefibrotic/Early Primary Myelofibrosis+2 more
University Hospital, Brest 1,308
Large-scale testing (Phase 3)Ended earlyNCT03755518
What this trial is testing

A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib

Who this might be right for
Primary MyelofibrosisPost-Polycythemia Vera MyelofibrosisMyelofibrosis+1 more
Celgene 38
Large-scale testing (Phase 3)Ended earlyNCT02962388
What this trial is testing

The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line

Who this might be right for
Essential Thrombocythemia
French Innovative Leukemia Organisation 13
Large-scale testing (Phase 3)Study completedNCT03952039
What this trial is testing

An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib

Who this might be right for
Primary MyelofibrosisPost-Polycythemia VeraMyelofibrosis
Celgene 202
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07750574
What this trial is testing

Flonoltinib Maleate Oral Regimens in Patients With Myelofibrosis

Who this might be right for
MyelofibrosisMyelofibrosis Due to and Following Polycythemia VeraMyelofibrosis Transformation in Essential Thrombocythemia+9 more
Chengdu Zenitar Biomedical Technology Co., Ltd 105
Large-scale testing (Phase 3)Study completedNCT00008359
What this trial is testing

Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment

Who this might be right for
Cancer
Memorial Sloan Kettering Cancer Center
Early research (Phase 1)Looking for participantsNCT06343805
What this trial is testing

LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)

Who this might be right for
Primary Myelofibrosis
Ajax Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company 256
Early research (Phase 1)Study completedNCT00004904
What this trial is testing

Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Who this might be right for
Chronic Myeloproliferative DisordersGraft Versus Host DiseaseLeukemia+5 more
Northwestern University
Testing effectiveness (Phase 2)Study completedNCT01787552
What this trial is testing

A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF

Who this might be right for
Primary MyelofibrosisThrombocytosisEssential Thrombocythemia+7 more
Novartis Pharmaceuticals 50
Testing effectiveness (Phase 2)Study completedNCT02556931
What this trial is testing

Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies

Who this might be right for
Myelodysplastic SyndromeChronic Myelomonocytic LeukemiaSmall Lymphocytic Lymphoma+11 more
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 117
Large-scale testing (Phase 3)Ended earlyNCT01437787
What this trial is testing

Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis

Who this might be right for
Hematopoietic Neoplasm
Bristol-Myers Squibb 289
Testing effectiveness (Phase 2)Ended earlyNCT00066417
What this trial is testing

Peripheral Stem Cell Transplant in Treating Patients With High-Risk Leukemia

Who this might be right for
Chronic Myeloproliferative DisordersLeukemiaMyelodysplastic/Myeloproliferative Diseases
National Heart, Lung, and Blood Institute (NHLBI) 51
Early research (Phase 1)Study completedNCT00588991
What this trial is testing

Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders

Who this might be right for
Adult Acute Megakaryoblastic LeukemiaAdult Acute Monoblastic LeukemiaAdult Acute Monocytic Leukemia+20 more
National Cancer Institute (NCI) 12
Large-scale testing (Phase 3)Study completedNCT02076815
What this trial is testing

Anagrelide Retard in Essential Thrombocythemia

Who this might be right for
Essential Thrombocythemia
AOP Orphan Pharmaceuticals AG 106
Large-scale testing (Phase 3)Study completedNCT01259856
What this trial is testing

Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)

Who this might be right for
High Risk Polycythemia VeraHigh Risk Essential Thrombocythemia
Ronald Hoffman 168
Testing effectiveness (Phase 2)Active Not RecruitingNCT02577926
What this trial is testing

The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia

Who this might be right for
Polycythemia Vera (PV)Essential Thrombocythemia (ET)
RWTH Aachen University 207
Early research (Phase 1)UnknownNCT00004036
What this trial is testing

Combination Chemotherapy Plus Amifostine in Treating Patients With Advanced Cancer

Who this might be right for
Chronic Myeloproliferative DisordersDrug/Agent Toxicity by Tissue/OrganLeukemia+5 more
The Cleveland Clinic 30
Next Page